A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co–V2 pandemic

[1]  Ming‐Lung Yu,et al.  Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuan, a hyperendemic area of southern Taiwan , 2022, The Kaohsiung journal of medical sciences.

[2]  Ming‐Lung Yu,et al.  Clinical characteristics and treatment outcomes of SARS-CoV-2 delta variant outbreak, Pingtung, Taiwan, June 2021 , 2022, Journal of the Formosan Medical Association.

[3]  Ming‐Lung Yu,et al.  Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan , 2021, BMJ Open.

[4]  Mark R. Marten,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 , 2021, Autophagy.

[5]  Shang-Jyh Hwang,et al.  Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C) , 2020, Gut.

[6]  Ming‐Lung Yu,et al.  Scaling up the in-hospital hepatitis C virus care cascade in Taiwan , 2020, Clinical and molecular hepatology.

[7]  H. Nomura,et al.  HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort , 2020, Hepatology International.

[8]  G. Dore,et al.  Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic. , 2020, The Journal of infectious diseases.

[9]  J. Pawlotsky,et al.  Impact of COVID-19 on global HCV elimination efforts , 2020, Journal of Hepatology.

[10]  C. James,et al.  The impact of COVID-19 on hepatitis elimination , 2020, The Lancet Gastroenterology & Hepatology.

[11]  R. Koretz.  USPSTF recommends screening adults 18 to 79 years for hepatitis C virus infection (moderate certainty) , 2020, Annals of Internal Medicine.

[12]  Ming‐Lung Yu,et al.  Importation of SARS-CoV-2 infection leads to major COVID-19 epidemic in Taiwan , 2020, International Journal of Infectious Diseases.

[13]  Sheng-Nan Lu,et al.  Secular Trends and Geographic Maps of Hepatitis C Virus Infection among 4 Million Blood Donors in Taiwan from 1999 to 2017 , 2020, Hepatology communications.

[14]  A. Tamori,et al.  Cure With Interferon‐Free Direct‐Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma From Both East and West , 2020 .

[15]  J. Kao,et al.  2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. , 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.

[16]  J. Kao,et al.  2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. , 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.

[17]  Stephen R. Spriggs,et al.  CDC Recommendations for Hepatitis C Screening Among Adults — United States, 2020 , 2020, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[18]  Ming‐Lung Yu,et al.  Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy , 2020, Clinical and molecular hepatology.

[19]  M. Ghany,et al.  Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection , 2020 .

[20]  Ding‐Shinn Chen.  Taiwan commits to eliminating hepatitis C in 2025. , 2019, The Lancet. Infectious diseases.

[21]  T. Hallett,et al.  Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model , 2019, The Lancet.

[22]  J. Lazarus,et al.  Micro-elimination - A path to global elimination of hepatitis C. , 2017, Journal of hepatology.

[23]  Ming‐Lung Yu,et al.  Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment , 2016, Clinical Cancer Research.

[24]  T. Tseng,et al.  Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients. , 2015, Journal of the Formosan Medical Association = Taiwan yi zhi.

[25]  Ming‐Lung Yu,et al.  Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C , 2015, Medicine.

[26]  A. Moorman,et al.  Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  A. Flaxman,et al.  Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.

[28]  Ming‐Lung Yu,et al.  Viral Hepatitis Infections in Southern Taiwan: A Multicenter Community‐based Study , 2010, The Kaohsiung journal of medical sciences.

[29]  P. Marcellin,et al.  Review article: management of patients with chronic hepatitis C virus infection and ‘normal’ alanine aminotransferase activity , 2006, Alimentary pharmacology & therapeutics.

[30]  Y. Liaw,et al.  A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. , 2006, Hepatology.

[31]  V. de Lédinghen,et al.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.

[32]  Ming‐Lung Yu,et al.  Hepatitis C virus infection among teenagers in an endemic township in Taiwan: epidemiological and clinical follow-up studies. , 2002, Epidemiology and infection.

[33]  Ming‐Lung Yu,et al.  Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan , 2001, Journal of medical virology.

[34]  G. Ioannou,et al.  HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. , 2017, Journal of hepatology.

[35]  Chien-Hung Chen,et al.  Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. , 2007, Journal of the Formosan Medical Association = Taiwan yi zhi.